Combating SARS-CoV-2 Pandemic
A global approach coupling powerful state-of-the-art virologic and immunologic platforms with large genomic surveillance studies and diverse cohorts in EU and SSA
EU-Africa Concerted Action
CoVICIS: EU-Africa Concerted Action on SARS-CoV-2 Virus Variant and Immunological Surveillance
CoVICIS is a three year project funded by the EU Horizon Europe program. It is led by Centre Hospitalier Universitaire Vaudois (CHUV) involving 14 partners from 7 countries – Switzerland, Italy, France, Germany, the Netherlands, Ethiopia and South Africa. CoVICIS’ unique strength is its combined expertise with world leading scientists in the fields of epidemiology, genomics, virology, immunology, data science and public health, coupled with state-of-the-art cutting edge technologies in bioscience.
Contributing to the early identification of emerging VOC
Obtaining in-depth understanding of the risk and protective factors to SARS-CoV-2 infection as well as the evolution of the virus in different risk, gender and age groups
Our five main objectives are:
Identifying emerging new VOCs through genomic surveillance in different cohorts;
Deciphering the risk and protective factors to infection in different risk, gender and age groups;
Evaluating the impact of VOCs on the effectiveness of vaccines induced humoral and cellular responses in different populations and regions in the EU and SSA;
Identifying immune correlates of protection against VOC through the development of algorithms predicting the impact of emerging VOC on the efficacy of vaccines; and
Informing the future vaccination strategy and design of next generation of vaccines.
CoVICIS is funded by the European Union’s Horizon Europe Research and Innovation Programme under grant nr 101046041